Medical News

RSS

Alcon second-quarter adjusted EPS increases 14.4% to $2.22 per share

The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.

27 Jul 2010

Childhood cancer survival associated with high risk of abnormal cardiac function

Childhood cancer survival is associated with increased risk of long-term abnormalities in cardiac function, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jul 2010

Medical device complications send more than 70,000 kids to ER annually

The Associated Press: The first detailed national estimate on complications in medical device use by children says that more than 70,000 kids a year have to go to emergency rooms because of complications from medical devices, with contact lenses the leading culprit. "About one-fourth of the problems were things like infections and eye abrasions in contact lens wearers.

27 Jul 2010

SonoSite second-quarter revenue increases 18% to $61.5 million

SonoSite, Inc., the world leader and specialist in hand-carried ultrasound for the point-of-care, today reported financial results for the second quarter and first half ended June 30, 2010.

27 Jul 2010

Novartis launches new OTC children's liquid acetaminophen product

Novartis announces the introduction of Triaminic™ Fever Reducer Pain Reliever, the only branded over-the-counter children's liquid acetaminophen product currently available nationwide in the US. Triaminic® now offers parents a product that combines the pain relieving and fever-reducing power of acetaminophen with the brand that has been trusted by pediatricians and parents for more than 50 years.

27 Jul 2010

GenVec creates novel vectors for vaccine development

GenVec, Inc. announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.

27 Jul 2010

Safety-net hospitals fear fiscal effects of health overhaul

"The hard-fought health reforms slowly taking shape across the country are intended to help provide better access to care -- but they could mean financial trouble for so-called 'safety-net' hospitals that take care of the poor," The Fresno Bee reports. "Already, hospital officials say millions in payments have been cut this year for Medicare patients in California, and they expect billions of dollars in cuts over the next 10 years for Medicare and Medi-Cal, as government tightens spending to help cover more people.

27 Jul 2010

Pilot program to confront major eDiscovery challenges in life sciences

eDiscovery for Pharma, Biotech and Medical Device Industries will be the key meeting of the year for eDiscovery experts in the life science space. This event will bring together leading eDiscovery experts to confront the major eDiscovery challenges specific to pharmaceutical, biotech, and medical device industries.Attendees will learn best eDiscovery practices to help prepare organizations for FDA inquiries, patent litigation, HIPAA compliance and data security issues; plus CLE credits are available.

27 Jul 2010

MAQUET Cardiovascular launches VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting System

MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.

27 Jul 2010

Teva second-quarter net sales increase 12% to $3.8 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010.

27 Jul 2010

Affymetrix releases new data for rapid design of custom arrays

Affymetrix, Inc.today announced that it has released an unparalleled data set based on extensive validation of novel SNPs from the 1000 Genomes Project. This data will give researchers access to more rare mutations for genome-wide association studies and will enable the rapid design of custom arrays for a variety of applications, including the validation of sequencing results.

27 Jul 2010

Britain plans to decentralize NHS, tranfer budget to general practitioners

British officials are proposing a plan to decentralize the National Health Service, news outlets report.

27 Jul 2010

Study on interactions between new antitubercular drug candidates SQ109 and TMC207

Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate:

27 Jul 2010

AHF denies BMS sales reprepresentatives access to healthcare centers

Today AIDS Healthcare Foundation (AHF) announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb (BMS) from calling on AHF's medical providers and staff in its sixteen U.S. healthcare centers. The decision is based on BMS' refusal to lower the price of its key AIDS drug Reyataz for cash-strapped AIDS Drug Assistance Programs.

27 Jul 2010

Idenix second-quarter total revenues decrease to $1.3 million

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million.

27 Jul 2010

AU leaders summit kicks off, focus on maternal and child health

Heads of state from the African Union (AU) started a three-day meeting in Kampala, Uganda, on Sunday as part of the 15th AU Summit, People's Daily Online reports. Leaders will focus on maternal and child health and will discuss several other issues, including agricultural development, food security, infrastructure development and economic integration (7/26).

27 Jul 2010

Later sunset, extended daylight exposure delays bedtimes in teenagers

In the spring, later sunset and extended daylight exposure delay bedtimes in teenagers, according to researchers at Rensselaer Polytechnic Institute's Lighting Research Center (LRC).Biologically, this increased exposure to early evening light in the spring delays the onset of nocturnal melatonin, a hormone that indicates to the body when it's nighttime, explains Mariana Figueiro, Ph.D., associate professor. This extended exposure adds to the difficulties teens have falling asleep at a reasonable hour.

27 Jul 2010

Abviva to receive patent for its new Mammastatin technology

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks

27 Jul 2010

Johns Hopkins scientist wins $2.5M NIH Director's Pioneer Award

A Johns Hopkins scientist who proposes to design and create an all-new series of novel drugs is one of 17 winners of a special grant known as a Director's Pioneer Award from the National Institutes of Health.

27 Jul 2010

HealthStream second-quarter revenues increase 14% to $16.7M

HealthStream, Inc., a leading provider of learning and research solutions for the healthcare industry, announced today results for the second quarter ended June 30, 2010.

27 Jul 2010